Skip to main content
Top
Published in: memo - Magazine of European Medical Oncology 2/2019

01-06-2019 | Lymphoma | case report

Seasonal fever for 11 years! A presentation of hemophagocytic lymphohistiocytosis secondary to marginal zone lymphoma

Authors: Abhishek Chaturvedi, MD, Muhammad Salman Faisal, MD, Ahmed Khattab, MD, Joan Devine, MD, Dr. Prerna Mewawalla, MD

Published in: memo - Magazine of European Medical Oncology | Issue 2/2019

Login to get access

Summary

Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of excessive inflammation and immune activation.  The syndrome can be triggered by multiple events that disrupt immune homeostasis, including infection, autoimmune diseases, and lymphoma. Although more common in children—which might indicate a genetic cause—HLH can occur in patients of any age. The most common presenting features of HLH are fever, cytopenia, hepatitis, and splenomegaly. Other features include neurologic abnormalities such as altered mental status, seizures, and ataxia. It is a reactive process of antigen-presenting macrophages and CD8+ T‑cell activation and migration. In addition, abnormalities in the action or number of natural killer cells have been observed. Direct cytotoxicity from T cells, along with elevated levels of pro-inflammatory cytokines and interleukins, plays a role in the generation of excessive inflammation that leads to organ dysfunction. We present the case of a 61-year-old female patient with a past history of recurrent self-limiting episodes of fever that occurred two to three times every autumn for the past 11 years. The meticulous thought process that led to her diagnosis with HLH and marginal zone lymphoma is discussed.
Literature
1.
go back to reference Filipovich A, McClain K, Grom A. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S82–S9.CrossRef Filipovich A, McClain K, Grom A. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S82–S9.CrossRef
2.
go back to reference Risma K, Jordan MB. Hemophagocytic lymphohistiocytosis: updates and evolving concepts. Curr Opin Pediatr. 2012;24(1):9–15.CrossRef Risma K, Jordan MB. Hemophagocytic lymphohistiocytosis: updates and evolving concepts. Curr Opin Pediatr. 2012;24(1):9–15.CrossRef
3.
go back to reference Egeler RM, Shapiro R, Loechelt B, Filipovich A. Characteristic immune abnormalities in hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol. 1996;18(4):340–5.CrossRef Egeler RM, Shapiro R, Loechelt B, Filipovich A. Characteristic immune abnormalities in hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol. 1996;18(4):340–5.CrossRef
4.
go back to reference Pachlopnik Schmid J, Cote M, Menager MM, Burgess A, Nehme N, Menasche G, et al. Inherited defects in lymphocyte cytotoxic activity. Immunol Rev. 2010;235(1):10–23.CrossRef Pachlopnik Schmid J, Cote M, Menager MM, Burgess A, Nehme N, Menasche G, et al. Inherited defects in lymphocyte cytotoxic activity. Immunol Rev. 2010;235(1):10–23.CrossRef
5.
go back to reference Tang Y, Xu X, Song H, Yang S, Shi S, Wei J, et al. Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome. Br J Haematol. 2008;143(1):84–91.CrossRef Tang Y, Xu X, Song H, Yang S, Shi S, Wei J, et al. Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome. Br J Haematol. 2008;143(1):84–91.CrossRef
6.
go back to reference Arico M, Danesino C, Pende D, Moretta L. Pathogenesis of haemophagocytic lymphohistiocytosis. Br J Haematol. 2001;114(4):761–9.CrossRef Arico M, Danesino C, Pende D, Moretta L. Pathogenesis of haemophagocytic lymphohistiocytosis. Br J Haematol. 2001;114(4):761–9.CrossRef
7.
go back to reference Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31.CrossRef Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31.CrossRef
8.
go back to reference Lehmberg K, Sprekels B, Nichols KE, Woessmann W, Muller I, Suttorp M, et al. Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents. Br J Haematol. 2015;170(4):539–49.CrossRef Lehmberg K, Sprekels B, Nichols KE, Woessmann W, Muller I, Suttorp M, et al. Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents. Br J Haematol. 2015;170(4):539–49.CrossRef
9.
go back to reference Allory Y, Challine D, Haioun C, Copie-Bergman C, Delfau-Larue MH, Boucher E, et al. Bone marrow involvement in lymphomas with hemophagocytic syndrome at presentation: a clinicopathologic study of 11 patients in a Western institution. Am J Surg Pathol. 2001;25(7):865–74.CrossRef Allory Y, Challine D, Haioun C, Copie-Bergman C, Delfau-Larue MH, Boucher E, et al. Bone marrow involvement in lymphomas with hemophagocytic syndrome at presentation: a clinicopathologic study of 11 patients in a Western institution. Am J Surg Pathol. 2001;25(7):865–74.CrossRef
10.
go back to reference Chang Y, Cui M, Fu X, Han L, Zhang L, Li L, et al. Lymphoma associated hemophagocytic syndrome: a single-center retrospective study. Oncol Lett. 2018;16(1):1275–84.PubMedPubMedCentral Chang Y, Cui M, Fu X, Han L, Zhang L, Li L, et al. Lymphoma associated hemophagocytic syndrome: a single-center retrospective study. Oncol Lett. 2018;16(1):1275–84.PubMedPubMedCentral
12.
go back to reference Han A‑R, Lee HR, Park B‑B, Hwang IG, Park S, Lee SC, et al. Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. Ann Hematol. 2007;86(7):493.CrossRef Han A‑R, Lee HR, Park B‑B, Hwang IG, Park S, Lee SC, et al. Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. Ann Hematol. 2007;86(7):493.CrossRef
13.
go back to reference Yu J‑T, Wang C‑Y, Yang Y, Wang R‑C, Chang K‑H, Hwang W‑L, et al. Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution. Ann Hematol. 2013;92(11):1529–36.CrossRef Yu J‑T, Wang C‑Y, Yang Y, Wang R‑C, Chang K‑H, Hwang W‑L, et al. Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution. Ann Hematol. 2013;92(11):1529–36.CrossRef
14.
go back to reference Henter JI, Arico M, Egeler RM, Elinder G, Favara BE, Filipovich AH, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol. 1997;28(5):342–7.CrossRef Henter JI, Arico M, Egeler RM, Elinder G, Favara BE, Filipovich AH, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol. 1997;28(5):342–7.CrossRef
15.
go back to reference Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008;50(6):1227–35.CrossRef Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008;50(6):1227–35.CrossRef
16.
go back to reference Komp DM, McNamara J, Buckley P. Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes. Blood. 1989;73(8):2128–32.PubMed Komp DM, McNamara J, Buckley P. Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes. Blood. 1989;73(8):2128–32.PubMed
Metadata
Title
Seasonal fever for 11 years! A presentation of hemophagocytic lymphohistiocytosis secondary to marginal zone lymphoma
Authors
Abhishek Chaturvedi, MD
Muhammad Salman Faisal, MD
Ahmed Khattab, MD
Joan Devine, MD
Dr. Prerna Mewawalla, MD
Publication date
01-06-2019
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 2/2019
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-0487-4

Other articles of this Issue 2/2019

memo - Magazine of European Medical Oncology 2/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine